Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function.
The vesicular monoamine transporter-2 (VMAT-2) sequesters cytoplasmic dopamine (DA) into vesicles and may thus protect neurons from DA-associated oxidative damage. VMAT-2 function, as assessed by measuring [(3)H]DA uptake, is less in adolescent when compared with young adult rats and VMAT-2 susceptibility to methamphetamine also changes with age. Thus, developmental alterations in VMAT-2 function warrant further investigation. The current study extends these findings by showing that the initial velocities of both DA uptake and methamphetamine-induced DA efflux are less in adolescent postnatal day (PND 38-42) vs. young adult (PND 88-92) rats as assessed in nonmembrane associated (presumably cytoplasmic) vesicles purified from rat striatal synaptosomes. The decrease in DA uptake velocities is due to a decrease in the V(max) of DA uptake with no change in the K(m). The density of kinetically active VMAT-2 and VMAT-2 immunoreactivity are less in adolescent vs. young adult rats while both the turnover number (2.4-2.8 s(-) (1)) and rate constant for the association of DA with VMAT-2 ( 1 x 10(7) M(-) (1) s(-) (1)) are similar in these age groups. These results suggest that the kinetics of DA binding and translocation across the membrane are unaltered in the vesicles of PND 38-42 vs. PND 88-92 rats. However, decreased VMAT-2 density in PND 38-42 rats reduces V(max), which in turn lowers DA uptake.
Volz
Trent J
TJ
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, 84112, USA.
Hanson
Glen R
GR
Fleckenstein
Annette E
AE
D000375:Aging / Q000378:metabolism*; D000465:Algorithms; D000818:Animals; D015153:Blotting, Western; D004298:Dopamine / Q000378:metabolism; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D004594:Electrophysiology; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D007700:Kinetics; D008694:Methamphetamine / Q000494:pharmacology; D051381:Rats; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism; D050493:Vesicular Monoamine Transport Proteins / Q000378:metabolism*
D018765:Dopamine Uptake Inhibitors; C493454:Slc18a2 protein, rat; D050493:Vesicular Monoamine Transport Proteins; D008694:Methamphetamine; D004298:Dopamine